+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of SPT-300 GlyphAllo, a prodrug of allopregnanolone, in adults aged 18 to 65 years with major depressive disorder MDD, including those with or without anxious distress. This Phase 2 randomized, double-blind, placebo-controlled study aims to better understand how SPT-300 impacts depressive symptoms compared to placebo. Participants will be randomly assigned to receive either SPT-300 capsules or a matching placebo once daily for 42 days. The study is designed as a parallel-group trial with two arms one receiving the experimental drug SPT-300 and the other receiving placebo. Treatment effects will be closely monitored during this 6-week period. Throughout the study, participants will undergo assessments including the Hamilton Depression Rating Scale-17 HAM-D-17 and the Clinical Global Impression - Severity CGI-S to measure changes in depressive symptoms from baseline to day 42. Safety and tolerability will also be evaluated. The total participation duration extends until study completion in March 2027, with regular visits to monitor progress and well-being.

Age: 18Years - 65YearsAll GendersPhase 2
61 locations